CNO Financial Group, Inc.·4

Feb 12, 5:28 PM ET

Zimpfer Matthew J. 4

4 · CNO Financial Group, Inc. · Filed Feb 12, 2026

Research Summary

AI-generated summary of this filing

Updated

CNO General Counsel Matthew Zimpfer Sells 30,970 Shares

What Happened
Matthew J. Zimpfer, General Counsel of CNO Financial Group (CNO), sold 30,970 shares on Feb 12, 2026 for total proceeds of $1,329,582 (weighted avg. $42.93). The same day he exercised 30,970 option-derived shares (exercise cost $652,228 at $21.06 per share) and sold those shares under a 10b5-1 plan — a cashless exercise/sale. Separately, on Feb 10, 2026, 25,384 performance share units vested and converted into common stock (valued at $1,092,781 based on $43.05/share), of which 7,663 shares were surrendered to cover tax withholding. He was also granted 14,300 restricted stock units (RSUs) that convert one-for-one to shares but vest in three equal annual installments beginning March 25, 2027.

Key Details

  • Transaction dates and prices:
    • 2026-02-10: 25,384 PSUs vested → 25,384 shares acquired @ $43.05 (value $1,092,781).
    • 2026-02-10: 7,663 shares surrendered for tax withholding on the vested PSUs (at $43.05, value $329,892).
    • 2026-02-10: 14,300 RSUs granted @ $0.00 (convert 1-for-1; vesting begins 3/25/2027).
    • 2026-02-12: Exercised/converted 30,970 derivative shares @ $21.06 (exercise cost $652,228).
    • 2026-02-12: Sold 30,970 shares under a Rule 10b5-1 plan for total proceeds $1,329,582; weighted avg sale $42.93 (range $42.31–$43.75).
  • Net effect on beneficial ownership from this filing: a net increase of 17,721 shares (25,384 vested minus 7,663 surrendered for taxes). The exercised shares were sold same day, so they did not increase long-term shareholding.
  • Sale executed pursuant to a Rule 10b5-1 trading plan adopted June 9, 2025 (routine scheduled sale).
  • Vesting of the PSUs was performance-based (metrics: 2023 operating ROE, 2023 operating EPS, and three‑year relative TSR for 2023–2025).
  • RSUs reported convert 1-for-1 and vest over three years beginning March 25, 2027 (subject to continued employment).

Context

  • This was largely a routine package of equity compensation activity: performance shares vested (some withheld for taxes), options were exercised and immediately sold under a pre-established 10b5-1 plan (cashless exercise), and new RSUs were granted with future vesting.
  • Sales under pre-set 10b5-1 plans are typically scheduled and do not necessarily indicate a change in an insider’s view of the company; vested awards and RSU grants reflect compensation, not an open-market purchase signal.

Insider Transaction Report

Form 4
Period: 2026-02-10
Zimpfer Matthew J.
General Counsel
Transactions
  • Award

    Common Stock

    [F1]
    2026-02-10$43.05/sh+25,384$1,092,781301,300 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-10$43.05/sh7,663$329,892293,637 total
  • Award

    Restricted Stock Units

    [F3][F4]
    2026-02-10+14,300307,937 total
  • Exercise/Conversion

    Common Stock

    2026-02-12$21.06/sh+30,970$652,228338,907 total
  • Sale

    Common Stock

    [F5][F6]
    2026-02-12$42.93/sh30,970$1,329,582307,937 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    [F7]
    2026-02-1230,9700 total
    Exercise: $21.06Exp: 2027-02-23Common Stock (30,970 underlying)
Footnotes (7)
  • [F1]Shares were acquired upon the vesting of performance share units for the 2023-2025 performance period, based on the issuer's (i) 2023 operating return on equity, (ii) 2023 operating earnings per share and (iii) three-year relative total shareholder return for 2023-2025.
  • [F2]Shares were surrendered to the issuer to cover the required tax withholding on the vested performance share units.
  • [F3]Restricted stock units convert into common stock on a one-for-one basis.
  • [F4]The restricted stock units vest in three equal annual installments beginning March 25, 2027, subject to continued employment with the issuer or one of its subsidiaries.
  • [F5]Shares sold pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025.
  • [F6]Reflects the weighted average sale price. Shares were sold at prices ranging from $42.31 per share to $43.75 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  • [F7]One-half of the stock options vested on February 23, 2019, and one-half vested on February 23, 2020.
Signature
Heidi M. Krings, Attorney-in-Fact|2026-02-12

Documents

1 file
  • 4
    wk-form4_1770935320.xmlPrimary

    FORM 4